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Detection of anti-influenza A nucleoprotein antibodies in pigs using a
commercial influenza epitope-blocking enzyme-linked immunosorbent
assay developed for avian species
Janice R. Ciacci-Zanella, Amy L. Vincent,1 John R. Prickett, Silvia M. Zimmerman,
Jeffrey J. Zimmerman
Abstract. Influenza virus causes acute respiratory disease in pigs and is of concern for its potential public
health significance. Many subtypes of influenza virus have been isolated from pigs, and the virus continues to
evolve in swine populations. Current antibody assays have limited antigenic recognition, and accurate, broad-
spectrum, high through-put screening tests are needed to detect infections in swine herds and to aid in the
implementation of control measures. In the current study, a commercial blocking enzyme-linked
immunosorbent assay (ELISA) developed for the detection of Influenza A virus nucleoprotein antibodies in
avian species was evaluated for the detection of anti-influenza serum antibodies in swine. Serum samples used
to evaluate the test were archived samples from influenza research conducted at the U.S. Department of
Agriculture–Agricultural Research Service–National Animal Disease Center and included samples from
influenza-inoculated pigs (H1N1, H1N2, H2N3, and H3N2), contact-infected pigs, vaccinated pigs, and
negative controls. Based on samples of known status (n 5 453), a receiver operating characteristic (ROC)
curve analysis of the ELISA results estimated the optimized diagnostic sensitivity and specificity at 96.6%
(95% confidence interval [CI]: 92.3, 98.9) and 99.3% (95% CI: 97.6, 99.9), respectively. By using the cutoff
established in the ROC analysis, the assay was evaluated in pigs infected with 2 isolates of the 2009 pandemic
H1N1 virus. Overall, the assay showed excellent diagnostic performance against the range of influenza
subtypes investigated and could serve as a useful screening assay for swine.
Key words: Antibody; enzyme-linked immunosorbent assay; influenza; sensitivity; serology; specificity;
swine.
Introduction
Influenza is a globally important pathogen of
economic, veterinary, and public health concern.
Swine influenza viruses (SIVs) of the H1N1 subtype
have been continually circulating in pigs in the United
States for at least 70 years.12 In addition to the classic
swine lineage H1N1, a triple reassortant H3N2
emerged in 1998 and spread rapidly in the swine
population.10 Since the introduction of the triple
reassortant H3N2 in 1998, 3 predominant SIV
subtypes have circulated in U.S. swine: H1N1,
H1N2, and H3N2. The H1N1 viruses contain
hemagglutinin (HA) and neuraminidase (NA) from
the classic swine virus and the internal genes from the
triple reassortant H3N2 viruses (rH1N1); the H1N2
viruses contain HA from the classic swine virus and
contain NA and internal genes from the triple
reassortant H3N2 viruses.8,20
Since the introduction of the triple reassortant
internal gene (TRIG) cassette, an increase in the rate
of genetic change in North American swine influenza
isolates appears to have occurred in H1 virus
subtypes, and distinct genetic and antigenic clusters
have evolved.19 In Canada, in 2003 and 2004, H1N1
and H1N2 viruses with human-like HA and NA were
isolated from pigs.7 These viruses were wholly human
or reassortants with internal genes of classic swine
virus lineage. Since that time, reassortant viruses with
human-like HA and NA, but with the TRIG cassette,
were isolated from pigs across the United States.18
These human-like H1 viruses have become endemic in
the U.S. pig population and circulate concurrently
with the contemporary SIV described above as a newly
emerged genetic and antigenic cluster of H1 SIVs.18
Serologic assays for SIV are crucial to the diagnosis
of clinical disease, immunologic herd profiling for
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timing of vaccination, monitoring vaccine compli-
ance, and epidemiologic studies based on seropreva-
lence. Current serum antibody assay formats include
hemagglutination inhibition (HI), enzyme-linked im-
munosorbent assay (ELISA), and serum-virus neu-
tralization (SVN). Although these assays show
satisfactory diagnostic performance for the detection
of antibodies homologous to antigens in the assay
system, all demonstrate deficiencies related to detec-
tion of antibodies against heterologous influenza
viruses. In addition, test performance of HI and
SVN assays are affected by variation in nonstandar-
dized biological reagents and the level of technical
expertise.
The emergence of the human pandemic Influenza A
virus 2009 H1N1 with genes of swine origin4,6 further
highlighted the need for improved, rapid diagnostic
tests to investigate, surveil, and monitor the global
swine population for zoonotic events. Fulfillment of
this objective will require a serologic assay capable of
detecting antibodies against a broad range of
influenza subtypes, including the newly emerged SIV
subtypes and reassortants in North America and
Europe.1
The commercial avian influenza multispecies ELI-
SAa (AI-MS ELISA) was developed and validated for
the detection of antibodies against influenza virus in
avian species. The assay uses a monoclonal antibody
generated against human Influenza A virus subtype
H1N121 and recognizes a highly conserved epitope of
influenza A nucleoprotein (NP). The objective of the
current study was to evaluate the diagnostic perfor-
mance of the AI-MS ELISA by using serum from pigs
infected with influenza subtypes H1N1, H1N2,
H2N3, and H3N2 under experimental conditions.
Materials and methods
Experimental design
In study 1, the diagnostic performance of the AI-MS
ELISA was evaluated by using 453 samples derived from
previous influenza research conducted at the U.S. Depart-
ment of Agriculture–Agricultural Research Service–National
Animal Disease Center (USDA-ARS-NADC)9,15–19 and
additional unpublished experiments. The panel included
149 serum samples from animals exposed to Influenza A virus
subtypes H1N1, H1N2, H3N2, or H2N3 in 6 separate
experiments and 304 samples from negative control animals
(Table 1). All samples were tested by using the AI-MS
ELISA, and the results were evaluated by receiver operating
characteristic (ROC) analysis.23 In addition, 104 samples
from vaccinated, unchallenged animals were assayed for
purposes of comparison but were not included in the set of
results used to evaluate assay performance.
In study 2, sera derived from pigs experimentally
challenged with 2 different isolates of pandemic Influenza
A virus 2009 H1N1 were evaluated by the AI-MS ELISA
with positivity determined by using the cutoff value
established in study 1. The panel included samples from
40 pigs collected at multiple time points pre- and post-
exposure.
Viruses
Swine influenza viruses were isolated from outbreaks of
respiratory disease in pigs and grown in Madin–Darby
canine kidney cells or chicken embryos by using standard
techniques to produce challenge or vaccine stocks, as
previously described.9,15–19 Viruses included in the live-
exposure experiments were the following: A/SW/IA/15/1930
H1N1 (IA30), A/SW/MN/00194/2003 H1N2 (MN03), A/
SW/IA/00239/2004 rH1N1 (IA04), A/SW/OH/511445/2007
H1N1 (OH07), A/SW/MN/07002083/07 huH1N1 (MN07),
A/SW/MO/4296424/2006 H2N3 (MO06), A/SW/TX/4199-
2/98 H3N2 (TX98), and the pandemic influenza viruses A/
CA/04/2009 H1N1 (CA09) and A/Mexico/4108/09 H1N1
(MX09). Additional viruses included in the inactivated
vaccine studies were the following: A/SW/MN/1192/2001
H1N2 (MN01), A/SW/NC36883/2002 rH1N1 (NC02), A/
SW/KS/00246/2004 H1N2 (KS04), A/SW/IA/1945 H1N1
(IA45), A/SW/WI/1/1968 H1N1 (WI68), A/SW/IA/1973
H1N1 (IA73), A/SW/MN/37866/1999 H1N1 (MN99), A/
SW/NC/02023/2008 H1N1 (NC08), A/SW/OH/02026/2008
H1N1 (OH08), A/SW/MO/02060/2008 H1N1 (MO08), A/
SW/IA/02096/2008 H1N1 (IA08), A/SW/KY/02086/2008
H1N1 (KY08), A/SW/MN/02011/2008 H1N1 (MN08), A/
SW/MN/02093/2008 H1N1 (MN08-2), A/SW/MN/02053/
2008 huH1N1 (MN08-3), A/SW/NE/02013/2008 H1N1
(NE08), A/SW/NC/02084/2008 H1N1 (NC08), A/SW/TX/
01976/2008 H1N2 (TX08), and A/SW/IA/02039/2008
huH1N1 (IA08-hu).
Animals, treatments, and serum samples
Four-week-old cross-bred pigs were obtained from a
herd free of both SIV and Porcine reproductive and
respiratory syndrome virus (PRRSV) infections. The ani-
mals were group-housed in individual isolation rooms and
were cared for in compliance with the NADC Institutional
Animal Care and Use Committee. All the pigs were
administered ceftiofur crystalline-free acidb at the beginning
of the acclimation period. Before inoculation or vaccina-
tion, SIV was not detected in nasal swab samples and anti-
influenza antibodies were not detected by the serum HI
assay. Thus, all animals were demonstrated to be free of
SIV.
In study 1, a total of 453 serum samples were available
for the evaluation of the AI-MS ELISAa (Tables 1, 2). The
sample set was composed of 304 serum samples from 304
individual influenza-negative control animals and 149
serum samples from 84 influenza-infected animals. Exper-
imentally infected animals (n 5 44) received 2 ml of
approximately 1 3 105 50% tissue culture infectious dose
(TCID50) per milliliter of influenza virus intratracheally
while under anesthesia, as previously described.9,15–19 The
remaining 40 influenza-infected pigs were exposed to SIV
by contact with intratracheally inoculated animals begin-
ning 2 or 3 days after inoculation. Influenza subtypes,
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isolates, exposure route (intratracheal or contact), number
of pigs, and days of serum collection are listed in Table 1.
Serum samples (n 5 104) from influenza-vaccinated
and unchallenged animals were assayed but were not
included in the cumulative ROC analysis, which estab-
lished AI-MS ELISAa cutoffs and corresponding perfor-
mance estimates. Vaccinated pigs received intramuscular
injections of 1 3 106 TCID50 per milliliter or approxi-
mately 64–128 HA units of ultraviolet-inactivated influ-
enza virus combined with a commercial adjuvant,c
followed by a booster dose 2–3 weeks later. Serum was
collected after the initial dose (approximately 14 days
postvaccination) and again after the booster dose
(approximately 28 days after initial vaccination). Vaccine
isolate, the number of pigs, and the days of serum
collection are listed in Table 2.
In study 2, to evaluate the performance of the AI-MS
ELISA with sera collected from pigs infected with 2009
pandemic H1N1, assays were run by using the cutoff
established by analysis of study 1 samples. Experimentally
infected animals (n 5 40) received 2 ml of approximately 1
3 105 TCID50 per milliliter of pandemic influenza virus
intratracheally, as described above. Subsets of pigs were
subsequently bled at days 0, 3, 5, 7, 14, and 21
postinfection.
Assays
Hemagglutination inhibition. Sera were heat inactivated
at 56uC and treated to remove nonspecific agglutinators with a
20% suspension of kaolin,d followed by adsorption with 0.5%
turkey red blood cells (RBC). The HI assays were performed
with turkey RBCs by using homologous virus and anti-sera
with standard techniques (WHO Manual on Animal Influenza
Diagnosis and Surveillance, http://www.wpro.who.int/NR/
rdonlyres/EFD2B9A7-2265-4AD0-BC98-97937B4FA83C/
0/manualonanimalaidiagnosisandsurveillance.pdf).
AI-MS ELISA. The AI-MS ELISAa is licensed for the
detection of antibody to avian influenza virus in chicken,
turkey, duck, ostrich, and goose serum. Samples were
assayed in duplicate according to the manufacturer’s
protocol for testing avian sera by using 15 ml of porcine
sera diluted 10-fold in diluent provided by the manufac-
turer. The diluted serum was dispensed onto the NP-coated
plate and allowed to bind to the antigen. An anti-NP
antibody conjugate with horseradish peroxidase (HRP),
followed by 3,39,5,59-tetramethyl benzidine (TMB) sub-
strate, was then used as a color indicator. If present,
antibody in the sample competitively bound to the epitope
and blocked binding of the HRP conjugate. Color
development, inversely proportional to the amount of
anti-influenza virus antibodies in the test sample, was
determined by using an ELISA plate readere at a
wavelength of 650 nm. Data management and calculations
were performed by using software provided by the
manufacturer.a Results were reported as the ratio of the
sample optical density (OD) reading to the kit negative
control OD reading (S/N).
Analysis
Descriptive statistics were generated by using the
statistical software program JMP (version 7.0.2)f in study
1. The experimental design precluded a full factorial
analysis by analysis of variance (ANOVAg) at the level of
isolate, subtype, treatment, or day post-inoculation (DPI),
because the data were unbalanced across factors, and many
combinations of factors contained few responses. There-
Table 1. Blocking enzyme-linked immunosorbent assaya response by virus isolate, exposure, and day postinoculation (DPI).
Subtype Exposure isolate Route of exposure No. of pigs DPI No. of samples (n 5 453)
Mean S/N response and median 99%
interval (0.5%, 99.5%)*
NA{ NA Negative control 304 0 304 0.94 (0.541, 1.332)
H1N1 IA04 Intratracheal 5 14 5 0.30 (0.178, 0.403)
27 5 0.20 (0.156, 0.235)
Contact 10 14 10 0.33 (0.192, 0.503)
27 10 0.31 (0.216, 0.411)
IA30 Intratracheal 8 14 8 0.32 (0.220, 0.405)
21 8 0.33 (0.158, 0.492)
MN07-hu Intratracheal 3 14 3 0.31 (0.234, 0.389)
27 3 0.25 (0.224, 0.281)
Contact 10 14 10 0.39 (0.259, 0.528)
27 10 0.37 (0.272, 0.423)
OH07 Intratracheal 5 14 5 0.32 (0.207, 0.425)
33 5 0.27 (0.199, 0.353)
Contact 10 12 10 0.35 (0.212, 0.461)
31 10 0.36 (0.183, 0.536)
H1N2 MN03 Intratracheal 8 14 8 0.40 (0.314, 0.601)
8 21 8 0.39 (0.183, 0.673)
H2N3 MO06 Intratracheal 5 14 5 0.45 (0.196, 0.814)
Contact 10 17 10 0.62 (0.336, 0.839)
H3N2 TX98 Intratracheal 8 14 8 0.35 (0.256, 0.570)
28 8 0.26 (0.172, 0.570)
* S/N response is the ratio of the sample optical density (OD) reading to the kit negative control OD reading.
{ NA 5 not applicable.
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fore, ANOVAg was conducted only at the level of treatment
groups (intratracheal exposure, contact exposure, vacci-
nated, and unchallenged). Receiver operating characteristic
analyses were conducted for each treatment group by using
MedCalc version 10.4.0.0.h The influenza-negative data in
each ROC analysis were composed of the S/N result from
each of 304 individual negative control animals. In study 2,
a ROC analysis was not conducted because of the small
number of animals. Therefore, descriptive statistics with
mean and median 99 percentile were generated, and
positivity cutoff was based on ROC from study 1.
Results
In study 1, sera from known positive animals as
previously determined by HI were used in the
ELISA.a Mean S/N responses and median 99%
intervals (0.5%, 99.5%) for infected and vaccinated
pigs are reported in Tables 1 and 2, respectively. To
account for the sparse data points within some
combinations of factors, the distribution of responses
was summarized as the median 99% interval. The S/N
means and ROC area under the curve estimates and the
optimized S/N cutoffs with associated diagnostic
sensitivity and/or specificity estimates are presented in
Table 3. The ANOVAg analysis showed statistically
significant differences in S/N response among intratra-
cheally exposed, contact exposed, and vaccinated and
unchallenged groups. However, the ROC analysis
found no significant difference between the intratrache-
al and contact exposure groups. A ROC analysis based
on 149 samples from influenza-infected pigs (intratra-
cheal inoculated + contact groups) and 304 negative
control pigs estimated the optimized AI-MS ELISAa
cutoff as S/N $ 0.673, with corresponding diagnostic
sensitivity and specificity estimated at 96.6% (95%
confidence interval [CI]: 92.3, 98.9) and 99.3% (95% CI:
97.6, 99.9), respectively (Table 4, Fig. 1).
In study 2, by using the cutoff of 0.673 established
above, seroconversion in 2009 pandemic H1N1-infected
Table 2. Blocking enzyme-linked immunosorbent assaya response in unexposed, vaccinated animals by day post-vaccination (DPV).
Subtype Vaccine isolate No. of pigs DPV No. of samples (n 5 104)
Mean S/N response and median 99% interval
(0.5%, 99.5%)*
H1N1 IA04 2 28 2 0.29 (0.277, 0.310)
IA08 2 14 2 0.34 (0.268, 0.414)
28 2 0.24 (0.214, 0.266)
IA08-hu 2 14 2 0.97 (0.967, 0.979)
IA30 2 14 2 0.74 (0.625, 0.845)
28 2 0.44 (0.351, 0.523)
IA45 2 28 2 0.28 (0.260, 0.309)
IA73 2 28 2 0.23 (0.155, 0.296)
KY08 2 14 2 0.48 (0.312, 0.640)
28 2 0.32 (0.277, 0.353)
MN08 2 14 2 0.65 (0.450, 0.849)
28 2 0.35 (0.210, 0.484)
MN08-2 2 14 2 0.33 (0.270, 0.393)
28 2 0.26 (0.250, 0.261)
MN08-3 hu 2 14 2 0.42 (0.304, 0.527)
28 2 0.26 (0.196, 0.324)
MN99 2 28 2 0.40 (0.337, 0.466)
MO08 2 14 2 0.55 (0.363, 0.727)
28 2 0.20 (0.195, 0.197)
NC02 2 28 2 0.28 (0.264, 0.302)
NC08 4 14 4 0.64 (0.209, 1.212)
28 4 0.26 (0.225, 0.293)
NE08 2 14 2 0.63 (0.455, 0.795)
28 2 0.32 (0.265, 0.365)
OH08 2 14 2 0.43 (0.422, 0.429)
28 2 0.29 (0.285, 0.296)
WI68 2 28 2 0.37 (0.199, 0.540)
H1N2 IA08-hu 2 28 2 0.50 (0.480, 0.515)
KS04 2 28 2 0.35 (0.342, 0.354)
MN01 2 28 2 0.20 (0.186, 0.207)
MN03 2 28 2 0.41 (0.383, 0.445)
TX08 hu 2 14 2 0.55 (0.545, 0.554)
28 2 0.38 (0.329, 0.425)
H3N2 TX98 31 14 31 0.77 (0.552, 1.075)
3 28 3 0.30 (0.257, 0.316)
* S/N response is the ratio of the sample optical density (OD) reading to the kit negative control OD reading.
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pigs was detected as early as 5 DPI in 1 pig and in 9 of 10
pigs on 7 DPI. By 14 DPI, all pigs experimentally
challenged with CA09 or MX09 had S/N values below
the positive cutoff. The mean S/N values for pigs
infected with pandemic H1N1 are presented in Table 5.
Discussion
The AI-MS ELISAa used in the current study is an
epitope-blocking assay in which a labeled monoclonal
antibody directed against influenza A NP is blocked
from binding to the avian influenza NP-coated
microtiter plate in the presence of sample antibody
to NP. The monoclonal antibody used in the test was
generated by using human Influenza A virus subtype
H1N121 and recognizes a highly conserved epitope of
influenza A NP. Because the basis of the test is the
ability of sample antibody to bind and block a
conserved immunodominant epitope on the avian
influenza NP-coated solid phase, the assay format
does not require the use of species-specific reagents.
This makes the assay broadly applicable for any
species that generates an antibody response to the NP
protein of Influenza A virus.
Epitope-blocking assays are a preferred diagnostic
method when the pathogen has broad multispecies
transmissibility and when a defined conserved im-
munodominant epitope and paired monoclonal are
available. For example, multispecies blocking tests for
antibody detection have been developed and evalu-
ated for Foot-and-mouth disease virus,3 West Nile
virus,2 Avian pneumovirus subtype C,14 and Vesicular
stomatitis virus. Most influenza A multispecies
blocking tests reported in the literature use NP
detection as the basis of the assay.5,11,13,22 In a
previous study,5 a blocking ELISA format was
successfully used to detect anti-NP antibodies in
humans, ferrets, swine, horses, chickens, ducks,
guinea pigs, mice, and seals.
To the authors’ knowledge, the current study is the
first report of an influenza ELISA developed and
licensed for avian serum samples used to detect NP
antibodies in serum from pigs infected or vaccinated
with North American influenza viruses. The AI-MS
ELISAa showed excellent performance and detected
anti-influenza antibodies generated by the pig after
exposure to all SIV isolates tested as early as 5 days
postexposure (earliest sample collected). In contrast
to the 0.500 S/N cutoff recommended for avian serum
by the manufacturer, ROC analysis by using the
available panel of serum samples determined the
optimum cutoff for swine serum samples to be 0.673.
Because the ELISA is a blocking format, samples
#0.673 would be considered positive and .0.673
considered negative.
Table 3. Summary and comparison of blocking enzyme-linked immunosorbent assaya responses by treatment group.*
Treatment group Samples S/N (95% CI){ ROC AUC (95% CI){{ Optimized cutoff (diagnostic Se, Sp)
Vaccinated, unchallenged 104 0.51 (0.462, 0.560)A 0.939 (0.911, 0.960)A $0.853 (92.3, 83.5)
Contact exposure 70 0.39 (0.357, 0.423)B 0.994 (0.980, 0.999)B $0.664 (94.3, 99.6)
Intratracheal inoculation 79 0.33 (0.299, 0.354)C 0.999 (0.988, 1.000)B $0.673 (98.7, 99.6)
Contact + intratracheal 149 0.36 (0.334, 0.377) 0.997 (0.986, 1.000) $0.673 (96.6, 99.3)
Negative control 304 0.94 (0.931, 0.953) NA NA
* S/N 5 the ratio of the sample optical density (OD) reading to the kit negative control OD reading. CI 5 confidence interval; ROC 5
receiver operating characteristic; AUC 5 area under the curve; Se 5 sensitivity; Sp 5 specificity; NA 5 not applicable.
{ Levels not connected by same letter are significantly different.
{ ROC AUC analyses were based on results from 304 individual negative control pigs.
Table 4. Effect of commercial avian influenza multispecies enzyme-linked immunosorbent assaya S/N cutoff on assay diagnostic
sensitivity and specificity.*
S/N cutoff value Sensitivity (%) Specificity (%)
#0.40 71.81 (63.9, 78.9) 100.00 (98.8, 100.0)
#0.50 90.60 (84.7, 94.8) 99.67 (98.2, 100.0)
#0.60 94.63 (89.7, 97.7) 99.34 (97.6, 99.9)
#0.673{ 96.64 (92.3, 98.9) 99.34 (97.6, 99.9)
#0.70 96.64 (92.3, 98.9) 98.03 (95.8, 99.3)
#0.80 97.99 (94.2, 99.6) 92.76 (89.2, 95.4)
#0.90 100.00 (97.6, 100.0) 70.07 (64.6, 75.2)
* S/N 5 the ratio of the sample optical density (OD) reading to the kit negative control OD reading. Receiver operating characteristic
(ROC) analysis was based on 304 negative control samples and 149 positive samples from animals intratracheally or contact exposed to
influenza virus. Numbers in parentheses are 95% confidence intervals.
{ Cutoff calculated to optimize sensitivity and specificity derived from the ROC analysis.
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Serum samples from pigs vaccinated with whole-
virus vaccine demonstrated S/N responses in the
positive range, often after the first dose (14 days post-
vaccination [DPV]) and more reliably after the
booster dose (28 DPV). The delayed response to NP
in vaccinated animals is likely because of limited NP
in the inactivated vaccine preparation compared with
live challenge with virus replication in the host.
Nonetheless, the data suggest that the assay could
be useful for monitoring vaccine responses and on-
farm compliance of vaccine administration as well. In
addition, the assay has the potential to differentiate
infected from vaccinated animals if split-virus or
subunit vaccines that exclude NP are used. An area of
future investigation of the applicability of this assay is
for its potential to monitor maternal antibody decay
in piglets for vaccination timing.
The recent emergence of the 2009 H1N1 human
influenza pandemic virus4,6 has led to global aware-
ness of the need to increase surveillance in swine. The
current study demonstrates that the AI-MS ELISA
can rapidly detect antibody induced by infection with
pandemic H1N1 in addition to endemic North
American SIV. The assay can be incorporated as a
tool for diagnosing and monitoring outbreaks with
H1N1 or other influenza A viruses. The AI-MS
ELISAa provides an assay with standardized reagents
in a format compatible with the technology readily
available in most veterinary diagnostic laboratories
around the world. By extension, broad implementa-
tion of this assay could improve both the breadth and
the uniformity of serologic data for influenza virus at
a global level. Timely investigations should be
undertaken to determine the detection limitations of
the assay.
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Table 5. Blocking enzyme-linked immunosorbent assaya response by virus isolate and day postinoculation (DPI) in pandemic
H1N1-infected pigs.
Subtype Exposure isolate Route of exposure No. of pigs DPI No. of samples
Mean S/N response and median 99%
interval (0.5%, 99.5%)* No. positive
H1N1 CA09 Intratracheal 20 0 20 1.08 (0.887, 1.338) 0
3 5 0.96 (0.919, 0.992) 0
5 5 0.79 (0.504, 0.939) 1
7 5 0.60 (0.464, 0.905) 4
14 5 0.36 (0.252, 0.539) 5
21 5 0.37 (0.212, 0.524) 5
H1N1 MX09 Intratracheal 20 0 20 0.98 (0.810, 1.271) 0
3 5 0.99 (0.947, 1.027) 0
5 5 0.89 (0.816, 0.949) 0
7 5 0.48 (0.355, 0.626) 5
14 5 0.31 (0.223, 0.412) 5
21 5 0.29 (0.222, 0.346) 5
* S/N response is the ratio of the sample optical density (OD) reading to the kit negative control OD reading.
Figure 1. Results from the receiver operating characteristic
analysis on samples from influenza-infected pigs (intratracheal
inoculated + contact groups) and negative control pigs, which
estimated the optimized commercial avian influenza multispecies
enzyme-linked immunosorbent assaya (AI-MS ELISA) cutoff as
S/N $ 0.673, with corresponding diagnostic sensitivity and
specificity estimated at 96.6% and 99.3%, respectively.
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c. Emulsigen, MVP Laboratories Inc., Ralston, NE.
d. Sigma-Aldrich, St. Louis, MO.
e. Molecular Devices Corp., Sunnyvale, CA.
f. SAS Institute Inc., Cary, NC.
g. OriginLab, Northampton, MA.
h. MedCalc Software, Mariakerke, Belgium.
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